Trial
NCT01774851
A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Merrimack Pharmaceuticals
Collaborators
—
Condition
HER-2 Gene Amplification
Intervention
MM-111
Why stopped
DSMB recommendation due to lack of efficacy. There were no safety signals.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-22